Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept.

摘要: Cancers of the esophagus and stomach present a major health burden worldwide. In past 30 years we have witnessed some interesting shifts in terms epidemiology esophago gastric cancers. Regardless world region, majority patients diagnosed with esophageal or cancers die from progression recurrence their disease. While there are many active cytotoxic agents for cancers, impact on disease course has been modest at best. Median survival advanced gastroesophageal cancer is still less than year. Therefore, novel strategies, based our understanding biology genetics, desperately needed. Epidermal growth factor receptor (EGFR) pathway implicated pathophysiology epithelial malignancies, including EGFR inhibitors, small molecule tyrosine kinase inhibitors monoclonal antibodies, explored It appears that tumors distal junction (GEJ) may be more sensitive to blockade adenocarcinomas. Investigations looking into potential molecular predictors sensitivity GEJ ongoing. searching those predictors, it clear they will different ones identified lung colorectal Further development should driven by better disregulation drives patient population.